Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Tom D who wrote (292)	12/2/1997 7:28:00 PM
From: seminole	Read Replies (2) \| Respond to of 887

Tom and other DEPO FANS I live in San Diego and have recently been surrounded by DEPO recommendations. Apparently, the buzz is about their cancer drug and the Dec 18 FDA review. My review of the chart, broker's recommendations, income statement and balance sheet indicate this is good company/stock. But lets talk science. It seems to me that the impotance of this FDA review is not approval of a cancer drug but the approval of their drug delivery system. Is this true or has this DEPOFOAM technology been approved before? What are the patent implications of this drug delivery system? Will they be able to extend the patents of current drugs? (Example: taxol goes of patent protection but DepoTaxol gets patent protection) richard